期刊文献+

高效液相色谱法测定控释贴片中妥洛特罗的含量 被引量:4

Determination of tulobuterol in tulobuterol transdermal patch by HPLC
原文传递
导出
摘要 目的:建立高效液相色谱法测定妥洛特罗控释透皮贴片中药物含量的方法。方法:以三氯甲烷为萃取溶剂,超声10min充分提取贴片中药物,采用Promosil C18(4.6mm×250mm,5μm)色谱柱,甲醇-0.0015mol·L^-1庚烷磺酸钠溶液(以pH4.0的醋酸-醋酸钠缓冲液配制)(55:45)为流动相;流速1.0mL·min^-1;检测波长:220nm;柱温:30℃。结果:妥洛特罗在5~100μg·mL^-1范围内线性关系良好(r=0.9999),平均回收率为100.29%(RSD为1.23%,n=6)。结论:本方法准确可靠,稳定性好,可用于妥洛特罗控释贴片的质量控制。 OBJECTIVE To establish a high performance liquid chromatography (HPLC) method for the content determination of tulobuterol in transdermal patch. METHODS Chloroform was used as the extracted solvent, and the sample was processed ultrasonically for 10 min. A Promosil C18 column (4. 6 mm 250 mm, 5 μm) was adopted and the mobile phrase consisted of methanol-sodium heptanesulfonate solution(prepared by pH 4. 0 acetic acid-sodium acetate buffer solution)(55:45)at a flow rate of 1. 0 mL·min^-1. The detection wavelength was settled at 220 nm. The column temperature was maintained at 30 ~C. RESULTS The standard curve was fine linear in the range of 5 - 100 mg· L^-1 (r = 0. 999 9). The average recovery rate is 100. 29% and RSD is 1.23%(n = 6). The precision and stabilization of this method are all in accord with the test requirement. CONCLUSION The method is accurate,reliable, easy,and suitable for the quality control of tulobuterol transdermal patch.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2010年第12期996-999,共4页 Chinese Journal of Hospital Pharmacy
基金 湖北省"十一五"科技攻关重大专项"现代透皮制剂技术研究开发"(编号:2006AA304A07)
关键词 妥洛特罗 控释贴片 高效液相色谱法 含量测定 tulobuterol transdermal patch HPLC content determination
  • 相关文献

参考文献5

二级参考文献21

  • 1张援 ,许实波 ,朱良 ,陈颖 ,陈丽琼 ,马争 .格列美脲凝胶骨架控释贴剂的研制及大鼠体内药效学研究[J].中国药学杂志,2004,39(10):772-775. 被引量:8
  • 2韩启银,张根元,陶伟博,张君.高效液相色谱法测定苯磺酸氨氯地平分散片的含量[J].江苏药学与临床研究,2005,13(6):19-20. 被引量:7
  • 3陈国神,石一复.雌二醇控释贴片(周效)治疗妇女更年期综合征的临床研究[J].浙江省医学科学院学报,1996,7(3):1-3. 被引量:2
  • 4-.中国药典(二部)[M].,1995.附录80,附录89.
  • 5左向.Ciba-Geigy的estraderm TTS在英国上市[J].国外药讯,1987,(12):31-31.
  • 6姜连阁.Ciba-Geigy雌激素透皮制剂在英国上市[J].国外药讯,1989,(2):15-15.
  • 7[3]Kume H, Kondo M, Ito Y, et al. Effects of Sustained - release Tulobuterol On Asthma Control and Beta - adrenoceptor Function [ J ]. Clin Exp Pharmacol Physiol, 2002, 29(12): 1 076 - 1 083.
  • 8[4]Otsuka Saburo, Nakano Yoshihisa, Yamamoto Keiji. Percutaneous Preparation Comprising Tulobuterol: EP, 0677290 [ P ] 1995 - 10 - 18.
  • 9[5]Nakano Yoshihisa, Horiuchi Tetsuo, Fujivvara Sanae, et al. Percutaneous Preparation of Tulobuterol: US, 5571530[ P] 1996 - 11 - 05.
  • 10[6]Hans R, Hoffmann, Michael Horstmann. Transdermal Therapeutic System Comprising Tulobuterol as Active Substance: US, 5254348 [ P ] 1993 - 10 -19.

共引文献152

同被引文献26

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部